---
schema_version: "secwatch.filing_event.v1"
accession: "0000719135-22-000062"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:11:32.410846+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical Q2 revenue down 8% YoY; narrows 2022 guidance

## Summary
- Total revenue $10.3M (-8% YoY); Advanced Energy revenue $8.4M (-16% YoY), OEM $1.9M (+55%).
- Net loss $5.4M ($0.16 loss per share) vs $4.0M loss in Q2 2021; Adj. EBITDA loss $3.4M vs $2.4M.
- Full-year revenue guidance narrowed to $51-56.4M (prev $52.5-59M); net loss guidance widened to $20.1-16.6M.
- FDA granted 510(k) clearance for Renuvion Dermal Handpiece (wrinkles) and APR Handpiece (lax skin).
- International Advanced Energy generator and handpiece sales fell >45% and >30% YoY respectively.

## SEC filing metadata
- accession: 0000719135-22-000062
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000071913522000062/0000719135-22-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000071913522000062/apyx-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000719135-22-000062
- JSON: https://secwatch.observer/filing/0000719135-22-000062.json
- Plain text: https://secwatch.observer/filing/0000719135-22-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.